RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Shawn Spencer to Male

This is a "connection" page, showing publications Shawn Spencer has written about Male.
Connection Strength

0.064
  1. Bagde A, Mosley-Kellum K, Spencer S, Singh M. 3D DLP-printed cannabinoid microneedles patch and its pharmacokinetic evaluation in rats. J Pharm Pharmacol. 2024 Jun 06; 76(6):616-626.
    View in: PubMed
    Score: 0.014
  2. Backman JD, O'Connell JR, Tanner K, Peer CJ, Figg WD, Spencer SD, Mitchell BD, Shuldiner AR, Yerges-Armstrong LM, Horenstein RB, Lewis JP. Genome-wide analysis of clopidogrel active metabolite levels identifies novel variants that influence antiplatelet response. Pharmacogenet Genomics. 2017 04; 27(4):159-163.
    View in: PubMed
    Score: 0.008
  3. Dahut WL, Madan RA, Karakunnel JJ, Adelberg D, Gulley JL, Turkbey IB, Chau CH, Spencer SD, Mulquin M, Wright J, Parnes HL, Steinberg SM, Choyke PL, Figg WD. Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer. BJU Int. 2013 Jun; 111(8):1269-80.
    View in: PubMed
    Score: 0.006
  4. Lewis JP, Horenstein RB, Ryan K, O'Connell JR, Gibson Q, Mitchell BD, Tanner K, Chai S, Bliden KP, Tantry US, Peer CJ, Figg WD, Spencer SD, Pacanowski MA, Gurbel PA, Shuldiner AR. The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response. Pharmacogenet Genomics. 2013 Jan; 23(1):1-8.
    View in: PubMed
    Score: 0.006
  5. Waldmann TA, Conlon KC, Stewart DM, Worthy TA, Janik JE, Fleisher TA, Albert PS, Figg WD, Spencer SD, Raffeld M, Decker JR, Goldman CK, Bryant BR, Petrus MN, Creekmore SP, Morris JC. Phase 1 trial of IL-15 trans presentation blockade using humanized Mik?1 mAb in patients with T-cell large granular lymphocytic leukemia. Blood. 2013 Jan 17; 121(3):476-84.
    View in: PubMed
    Score: 0.006
  6. Troutman SM, Sissung TM, Cropp CD, Venzon DJ, Spencer SD, Adesunloye BA, Huang X, Karzai FH, Price DK, Figg WD. Racial disparities in the association between variants on 8q24 and prostate cancer: a systematic review and meta-analysis. Oncologist. 2012; 17(3):312-20.
    View in: PubMed
    Score: 0.006
  7. Patel AR, Spencer SD, Chougule MB, Safe S, Singh M. Pharmacokinetic evaluation and in vitro-in vivo correlation (IVIVC) of novel methylene-substituted 3,3' diindolylmethane (DIM). Eur J Pharm Sci. 2012 May 12; 46(1-2):8-16.
    View in: PubMed
    Score: 0.006
  8. Kummar S, Raffeld M, Juwara L, Horneffer Y, Strassberger A, Allen D, Steinberg SM, Rapisarda A, Spencer SD, Figg WD, Chen X, Turkbey IB, Choyke P, Murgo AJ, Doroshow JH, Melillo G. Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1a in advanced solid tumors. Clin Cancer Res. 2011 Aug 01; 17(15):5123-31.
    View in: PubMed
    Score: 0.006
  9. Li H, Qiang F, Yang Z, Spencer SD, Cui X, Wu X, Chen X. Hepatitis B virus with pre-S2 deletion is more prevalent in hepatocellular carcinoma than in chronic active hepatitis and asymptomatic carriers. Acta Virol. 2011; 55(2):183-5.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support